Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer.

Autor: Poumeaud F; Department of Medical Oncology, Oncopole Claudius Regaud, IUCT-O, Toulouse, France. poumeaud.francois@iuct-oncopole.fr., Morisseau M; Biostatistics & Health Data Science Unit, Oncopole Claudius Regaud IUCT-O, Toulouse, France., Cabel L; Department of Medical Oncology, Institut Curie, Paris, France., Gonçalves A; Aix-Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France., Rivier C; Department of Medical Oncology, Centre Léon Bérard, Cancer Research Center of Lyon (UMR Inserm 1052 - CNRS 5286), Lyon, France., Trédan O; Department of Medical Oncology, Centre Léon Bérard, Cancer Research Center of Lyon (UMR Inserm 1052 - CNRS 5286), Lyon, France., Volant E; Department of Medical Oncology, Institut de cancérologie de l'Ouest, Saint-Herblain, France., Frenel JS; Department of Medical Oncology, Institut de cancérologie de l'Ouest, Saint-Herblain, France., Ladoire S; Department of Medical Oncology, Centre Georges-François Leclerc, INSERM U1231, Dijon, France., Jacot W; Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier University, INSERM U1194, Montpellier, France., Jamelot M; Department of Medical Oncology and Cellular Therapy, Faculté de médecine Sorbonne Université, Hôpital Tenon, Paris, France., Foka Tichoue H; Department of Medical Oncology, Hôpital de la Pitié-Salpêtrière, Institut Universitaire de Cancérologie AP-HP, Sorbonne Université, Paris, France., Patsouris A; Department of Medical Oncology, Institut de Cancérologie de l'Ouest Pays de la Loire, Angers, France., Teixeira L; Department of Medical Oncology, INSERM U976, Université de Paris Cité, Hopital Saint Louis, Paris, France., Bidard FC; Department of Medical Oncology, Institut Curie, Saint-Cloud, France.; Versailles Saint-Quentin University, Paris Saclay, Saint-Cloud, France., Loirat D; Department of Medical Oncology, Institut Curie, Paris, France., Brunet M; Clinical Trials Department - Breast Cancers, Institut Bergonié, Bordeaux, France., Levy C; Department of Medical Oncology, Centre François Baclesse, Caen, France., Bailleux C; Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France., Cabarrou B; Biostatistics & Health Data Science Unit, Oncopole Claudius Regaud IUCT-O, Toulouse, France., Deleuze A; Department of Medical Oncology, Centre Eugène Marquis, Rennes, France., Uwer L; Department of Medical Oncology, Institut de Cancérologie de Lorraine, Nancy, France., Deluche E; Department of Medical Oncology, Centre Hospitalier Universitaire de Limoges, Limoges, France., Grellety T; Department of Medical Oncology, Centre Hospitalier de la côte basque, Bayonne, France., Franchet C; Department of Pathology, Oncopole Claudius Regaud, IUCT-O, Toulouse, France., Fiteni F; Department of Medical Oncology, University Hospital, Nimes, France.; UMR INSERM IDESP-Desbrest Institute of Epidemiology and Public Health, University of Montpellier, Montpellier, France., Bischoff H; Department of Medical Oncology, Institut de Cancérologie de Strasbourg Europe, Strasbourg, France., Vion R; Department of Medical Oncology, Centre Henri Becquerel, Rouen, France., Pagliuca M; University Paris-Saclay, Gustave Roussy, INSERM U981, Molecular Predictors and New Targets in Oncology, Villejuif, France.; Division of Breast Medical Oncology, Instituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, Italia., Verret B; Departmentof Medical Oncology, Institut Gustave Roussy, Paris, France., Bécourt S; Department of Medical Oncology, Centre Oscar Lambret, Lille, France., Reverdy T; Department of Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), Université Lyon 1, Lyon, France., de Nonneville A; Aix-Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France., Dalenc F; Department of Medical Oncology, Oncopole Claudius Regaud, IUCT-O, Toulouse, France.
Jazyk: angličtina
Zdroj: British journal of cancer [Br J Cancer] 2024 Sep; Vol. 131 (4), pp. 702-708. Date of Electronic Publication: 2024 Jun 25.
DOI: 10.1038/s41416-024-02766-9
Abstrakt: Background: Current guidelines recommend that patients with HER2-low metastatic breast cancer (MBC) receive sequentially two antibody-drug conjugates (ADCs): Sacituzumab Govitecan (SG) and Trastuzumab Deruxtecan (T-DXd), despite a similar payload. However, the effectiveness of one after another is unknown.
Methods: ADC-Low is a multicentre, retrospective study evaluating the efficacy of SG and T-DXd, one after another, with or without intermediary lines of chemotherapy, in patients with HER2-low MBC.
Results: One hundred and seventy-nine patients were included: the majority with HR-negative tumours received SG first (ADC1) (n = 100/108) while most with HR-positive tumours received T-DXd first (n = 56/71). Median progression-free survival 2 was short: 2.7 months (95% CI: 2.4-3.3) in the whole population, respectively, 3.1 (95% CI: 2.6-3.6) and 2.2 months (95% CI: 1.9-2.7) for patients receiving T-DXd or SG second (ADC2). Intermediary lines of chemotherapy between ADC1 and ADC2 had no impact. Primary resistance to ADC2 occurred in 54.4% of patients. Certain patients showed initial response to ADC2.
Conclusions: Clinical benefit of sequentially administered SG and T-DXd is limited for most patients. Nevertheless, a subset of patients might benefit-on the short term-from a second ADC. Additional studies are needed to identify patients who could benefit from two ADCs with similar payloads.
(© 2024. The Author(s), under exclusive licence to Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: